What happened
Summit Therapeutics said the Food and Drug Administration refused to approve its application to use ivonescimab in a niche slice of advanced non small cell lung cancer. The agency sent a Complete Response Letter saying it could not clear the filing as submitted because the drug failed to show a statistically significant improvement in how long patients lived.
The company noted the medicine did hold tumors in check, but regulators said that effect by itself did not justify approval. The decision focused on patients whose cancers are driven by EGFR gene mutations and whose common first line therapy either did not work or stopped working. Summit had sought approval after prior treatment with drugs that target EGFR.
The drug and the data
Ivonescimab was created by Akeso in China, which also sells it there, and Summit is partnering to bring it to the US. The medicine is billed as the most advanced dual action cancer immunotherapy, working both to rally the immune system and to hit a driver of tumor blood vessel growth.
In 2024, Summit and Akeso said the drug beat Merck's Keytruda in a Chinese late stage trial, a splash that helped spark a wave of licensing deals for similar China originated therapies. Since then, ivonescimab has become a bellwether for whether Chinese clinical wins can carry over globally, and Sunday's FDA outcome pushes that proof point further out. Summit pursued this EGFR setting despite prior regulator warnings that its data were not strong enough, and, in an Oct. 27 note, Jefferies called the approval odds "minimal."
New developments in healthcare underscore how staying informed helps investors find opportunities. We're hosting our first ever investor livestream on 11/17 to show you how to use ChatGPT and Claude to invest like a pro, hosted by Briefs Finance CEO Jaspreet Singh. Save your seat.
What the company will do next
Summit said it will keep evaluating the drug in other cancers and is running several additional global Phase 3 studies, including head to head trials against Keytruda. "We are disappointed for patients and their families awaiting additional treatment options in this setting," Chief Executive Officer Bob Duggan said, adding, "Our mission remains to improve outcomes for patients facing significant unmet needs, which is work worth doing."
In September, AstraZeneca Plc said it would put $2 billion into Summit to collaborate on ivonescimab and test it in combinations with AstraZeneca medicines. Should the ongoing trials succeed, Bloomberg Intelligence projects the therapy's total sales could hit $3.8 billion by 2030, and Akeso would collect low double digit royalties from US product sales.
Why investors might care
This setback hits a target population Summit previously pegged at more than 14,000 US patients a year, while Bloomberg Intelligence's Javier Manso Polo now forecasts that potential sales would amount to only $230 million by 2035. The bottom line: the US opportunity now rests on Summit proving ivonescimab's benefit in broader Phase 3 programs, including direct contests with Keytruda.
When industries shift, investors can gain an edge by using smarter research tools. On 11/17, our CEO Jaspreet Singh goes live for our first ever investor livestream on how to use ChatGPT and Claude to invest like a pro. Register to join him.
